Drug Trial Radar · NCT03975829
Pediatric Long-Term Follow-up and Rollover Study
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
163
Actual
Start
Nov 4, 2019
Primary completion
Nov 24, 2026
Study completion Nov 24, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
Conditions
- Diffuse Astrocytoma
- Anaplastic Astrocytoma
- Astrocytoma
- Oligodendroglioma, Childhood
- Anaplastic Oligodendroglioma
- Glioblastoma
- Pilocytic Astrocytoma
- Giant Cell Astrocytoma
- Pleomorphic Xanthoastrocytoma
- Anaplastic Pleomorphic Xanthoastrocytoma
- Angiocentric Glioma
- Chordoid Glioma of Third Ventricle
- Gangliocytoma
- Ganglioglioma
- Anaplastic Ganglioglioma
- Dysplastic Gangliocytoma of Cerebrellum
- Desmoplastic Infantile Astrocytoma and Ganglioglioma
- Papillary Glioneuronal Tumor
- Rosette-forming Glioneuronal Tumor
- Central Neurocytoma
- Extraventricular Neurocytoma
- Cerebellar Liponeurocytoma
- Neurofibromatosis Type 1
Interventions
dabrafenibDrug
dabrafenib oral, twice daily
trametinibDrug
trametinib oral, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events and Serious Adverse Events (SAEs)Time frame: Baseline up to approximately 7 years
Locations
54 sites in 19 countries. Site status is shown where the registry gives one.
Phoenix Children s Hospital
Phoenix, Arizona
Childrens National Hospital
Washington D.C., District of Columbia
Nicklaus Childrens Hospital
Miami, Florida
Indiana Uni School of Medicine
Indianapolis, Indiana
Johns Hopkins Hospital
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
University of Minnesota
Minneapolis, Minnesota
Memorial Sloan Kettering Cancer Ctr
New York, New York
Cinn Children Hosp Medical Center
Cincinnati, Ohio
St Jude Childrens Research Hospital
Memphis, Tennessee
Texas Childrens Hospital
Houston, Texas
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Darlinghurst, New South Wales, Australia
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Barretos, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Tampere, Finland, Finland
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Rennes, France
Novartis Investigative Site
Vandœuvre-lès-Nancy, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Rennes, Brittany Region, France
Novartis Investigative Site
Augsburg, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Petah Tikva, Israel
Novartis Investigative Site
Florence, FI, Italy
Novartis Investigative Site
Genova, GE, Italy
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.